Endoxifen, a protein kinase C inhibitor and selective estrogen receptor modulator, has originally been associated with breast cancer treatment but recently has emerged as a potential therapeutic option for managing manic episodes associated with bipolar disorder. The gene discussed is ESR1; the disease is breast carcinoma.